RALGAPB and oral cavity squamous cell carcinoma: A study in oral squamous cell carcinoma [10] showed that RALGAPB silencing increased the level of RalA activation, promoting HSC-2 cell migration and invasion in vitro, a profile characteristic of metastatic cells.